Dianthus Therapeutics, Inc. /DE/ SEC filings DNTH
Dianthus Therapeutics, Inc. /DE/ has 658 filings in SEC EDGAR's recent list, going back to Nov 23, 2016. Its latest annual report, Form ARS, was filed on Apr 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jan 30, 2026 | — |
| CORRESP | Letter to the SEC | Jan 29, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 29, 2026 | — |
| RW | Filing | Oct 21, 2024 | — |
| EFFECT | Filing | Oct 9, 2024 | — |
| EFFECT | Filing | Oct 9, 2024 | — |
| CORRESP | Letter to the SEC | Oct 7, 2024 | — |
| CORRESP | Letter to the SEC | Oct 7, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 7, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 7, 2024 | — |
| EFFECT | Filing | Mar 27, 2024 | — |
| CORRESP | Letter to the SEC | Mar 25, 2024 | — |
| CORRESP | Letter to the SEC | Feb 7, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 28, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2023 | — |
| 425 | Filing | Aug 31, 2023 | — |
| EFFECT | Filing | Aug 1, 2023 | — |
| CORRESP | Letter to the SEC | Jul 31, 2023 | — |
| CORRESP | Letter to the SEC | Jul 17, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 6, 2023 | — |
| CORRESP | Letter to the SEC | Jun 22, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 13, 2023 | — |
| 425 | Filing | May 19, 2023 | — |
| 8-A12B | Filing | May 3, 2023 | — |
| 425 | Filing | May 3, 2023 | — |
| 8-A12B | Filing | Mar 31, 2023 | — |
| EFFECT | Filing | Aug 12, 2022 | — |
| CORRESP | Letter to the SEC | Aug 10, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 9, 2022 | — |
| EFFECT | Filing | Jul 9, 2021 | — |
| CORRESP | Letter to the SEC | Jul 6, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 1, 2021 | — |
| CT ORDER | Filing | Dec 21, 2020 | — |
| CT ORDER | Filing | Sep 10, 2019 | — |
| EFFECT | Filing | Aug 19, 2019 | — |
| CORRESP | Letter to the SEC | Aug 14, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2019 | — |
| EFFECT | Filing | May 1, 2019 | — |
| CORRESP | Letter to the SEC | Apr 29, 2019 | — |
| CORRESP | Letter to the SEC | Apr 29, 2019 | — |
| CT ORDER | Filing | Apr 11, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 4, 2019 | — |
| DRS | Filing | Mar 29, 2019 | — |
| EFFECT | Filing | Jun 20, 2018 | — |
| CT ORDER | Filing | Jun 20, 2018 | — |
| CERT | Filing | Jun 20, 2018 | — |
| 8-A12B | Form 8-a12b | Jun 19, 2018 | — |
| CORRESP | Letter to the SEC | Jun 18, 2018 | — |
| CORRESP | Letter to the SEC | Jun 18, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 8, 2018 | — |
| CORRESP | Letter to the SEC | Jun 8, 2018 | — |
| CORRESP | Letter to the SEC | May 31, 2018 | — |
| CORRESP | Letter to the SEC | May 24, 2018 | — |
| UPLOAD | Letter from the SEC | May 16, 2018 | — |
| DRS/A | Filing | May 8, 2018 | — |
| DRSLTR | Filing | May 7, 2018 | — |
| UPLOAD | Letter from the SEC | Apr 24, 2018 | — |
| D | Filing | Apr 9, 2018 | — |
| DRS | Filing | Mar 28, 2018 | — |
| D | Filing | May 5, 2017 | — |
| D | Filing | Nov 23, 2016 | — |
Showing 61 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DNTH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1690585
- Former names
- Magenta Therapeutics, Inc. (until Sep 8, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.